Great talk. thanks oscar for link. Can't believe I waited this long to actually hear the whole thing.
Many good points, including a couple of my favourites which I classify as happy clapper doctorine.
""fail early - fail cheap""
""we can either deliver it or we can't"
""mainly dealing with known products...simply have to demonstrate we can deliver the active in a sustainable and reproducible manner""
To me these comments are the essence of why my optimism remains on overdrive on these threads.
In summary all we are testing is whether the product can get in. It either does or it doesn't.
I would bet my house on it, or at least 10% of it, that if anything is progressing it works, because it would be so easy for them to test inhouse. fail early -fail cheap, if it doesn't get in they turf it. They already know it.
Secondly we mainly are dealing with known drugs, just need to show sustainability and reproducibility.
""the phase II/III are non complex studies as they are with known products.....a successful phase II trial of for example tretinon(acne) allows us to bypass phase III""
because it is a known product.
Other information
LMDB products (2) sold over 30000 units in first 12 months, cost $90 and $150.
We are increasing from 2 to 10 products this month with LMDB.
Also talked about having made $2.1 million dollars from products, in context it sounded like she was talking about the original elixia, but not sure.
Worth a listen if you haven't already.
- Forums
- ASX - By Stock
- small cap investor presentation april 8
Great talk. thanks oscar for link. Can't believe I waited this...
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Exceptional lithium assays uncovered at Falcon Lake – expanding mineralisation, big potential ahead
NEWS
Biotech innovator secures $5.5M R&D tax incentive refund – major boost for cutting-edge programs
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M |
Open | High | Low | Value | Volume |
0.2¢ | 0.2¢ | 0.2¢ | $240 | 120K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
50 | 43820232 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 43900696 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
50 | 43820232 | 0.002 |
15 | 30500508 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 43900696 | 24 |
0.004 | 14687379 | 14 |
0.005 | 22033532 | 10 |
0.006 | 19380067 | 10 |
0.007 | 5722471 | 6 |
Last trade - 10.00am 12/09/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |